We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Publications
Search our publications, laboratory reports, meeting statements, scheduling submissions and scheduling decisions.
Can't find what you’re looking for? You can also:
- search our Resources
- use the site search bar in the top right of this screen for more results.
Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Topic
- Committees and advisory bodies (383)
- Scheduling (national classification system) (164)
- Safety monitoring and information (26)
- Advertising (25)
- COVID-19 (11)
- Manufacturing (11)
- Medicinal cannabis hub (6)
- Clinical trials (5)
- Sunscreens (5)
- Compliance and enforcement (4)
- Fees and payments (4)
- Shortages and supply disruptions (4)
- Legislation (3)
- Import and export (2)
- Breast implant hub (1)
- Cosmetics (1)
- Labelling and packaging (1)
- Metal-on-metal hip replacement implants hub (1)
- Prescription opioids hub (1)
- Unique Device Identification (UDI) hub (1)
Search
758 result(s) found, displaying 126 to 150
-
Scheduling decisions (final)Final decision on proposed amendments to the Poisons Standard relating to palovarotene
-
Meeting statementsAdvisory Committee on Vaccines meeting statement for meeting 45, held on 4 October 2023.
-
Meeting statementsAdvisory Committee on Vaccines meeting statement for meeting 46, held on 29 November 2023.
-
Meeting statementsAdvisory Committee on Medicines meeting statement
-
Corporate reportsThis report provides information about our regulatory performance from 1 July 2022 to 30 June 2023.
-
Scheduling decisions (final)Read our notice of final decision to amend (or not amend) the current Poisons Standard in relation to bisacodyl, olopatadine and ibotenic acid.
-
Scheduling submissionsFind out about the public submissions on interim decisions for scheduling matters referred to the ACMS #42 and Joint ACMS-ACCS #34 meetings held in June 2023.
-
Meeting statementsRead key points of discussion from the meeting 12 of the Medical Devices Consumer Working Group (MDCWG).
-
Corporate reportsWe survey our stakeholders each year to help evaluate our performance and identify ways of improving.
-
Corporate reportsRead our 2023 stakeholder survey report, which aims to improve the way we work with our stakeholders.
-
Meeting statementsAdvisory Committee on Vaccines meeting statement
-
Meeting statementsRead our Communique from the 5th meeting of the Women's Health Products Working Group (WHPWG), 30 October 2023.
-
Corporate reportsMDSU provides practical advice and information about medical device safety.
-
Corporate reportsThe strategy outlines the approach we will use to identify, engage with, and educate stakeholders about regulatory requirements and our compliance outcomes.
-
Meeting statementsAdvisory Committee on Medicines meeting statement
-
Meeting statementsCommunique from the 4th meeting of the Women's Health Products Working Group (WHPWG), 31 July 2023
-
Scheduling decisions (final)Read the notice of final decisions to not amend the Poisons Standard in relation to ketamine, esketamine and methysergide
-
Meeting statementsFind out about the AIVC Recommendations for the Composition of Influenza Vaccines for Australia in 2024
-
Scheduling decisions (final)Read the notice of final decisions to not amend the Poisons Standard in relation to comfrey.
-
Meeting statementsAdvisory Committee on Vaccines meeting statement
-
Scheduling submissionsFind out about public submissions on scheduling matters referred to Advisory Committees meeting, held in June 2023
-
Scheduling decisions (interim)Interim decisions and invitation for further comment. Closing date: 2 November 2023
-
Meeting statementsCommunique from the meeting of the TGACC
-
Corporate reportsOverview of therapeutic goods advertising complaints handling and compliance for 2022-23
-
Scheduling decisions (final)Notification of amendments to the Poisons Standard in relation to final decision in relation to lead, joint ACMS-ACCS #34